Table 2.
Clinical characteristics of patients (N = 122)
Cohort (N = 122) |
Groups(%) | P | ||
---|---|---|---|---|
COPD (N = 61) |
Non-COPD (N = 61) |
|||
Age | 0.230 | |||
median | 66 | 67 | 66 | |
range | 45–89 | 50–83 | 45–89 | |
Sex | 0.680 | |||
Male | 116(95.1) | 59(96.7) | 57(93.4) | |
Female | 6(4.9) | 2(3.3) | 4(6.6) | |
Smoking history | 0.073 | |||
Never-smokers | 36(29.5) | 13(21.3) | 23(37.7) | |
Ever-smokers | 86(70.5) | 48(78.7) | 38(62.3) | |
Histology | 0.053 | |||
Adenocarcinoma | 48(39.4) | 19(31.1) | 29(47.5) | |
Squamous | 67(54.9) | 40(65.6) | 27(44.3) | |
Others | 7(5.7) | 2(3.3) | 5(8.2) | |
ECOG performance status | 0.752 | |||
0–1 | 120(98.4) | 60(98.4) | 60(98.4) | |
2–3 | 2(1.6) | 1(1.6) | 1(1.6) | |
Genetic profile | 0.037 | |||
EGFR | 4(3.3) | 1(1.6) | 3(4.9) | |
KRAS | 7(5.7) | 1(1.6) | 6(9.8) | |
Others | 3(2.5) | 1(1.6) | 2(3.3) | |
Negative | 36(29.5) | 14(23.0) | 22(36.1) | |
NA | 72(59.0) | 44(72.1) | 27(44.3) | |
Fibrosis score | 0.638 | |||
0 | 100(82.0) | 49(80.3) | 51(83.6) | |
≥1 | 22(18.0) | 12(19.7) | 10(16.4) | |
Emphysema score | 0.003 | |||
0 | 75(62.0) | 29(47.5) | 46(75.4) | |
≥ 1 | 47(38.0) | 32(52.5) | 15(24.6) | |
Baseline spirometry | 0.642 | |||
DLco% predicted* | 69.9(16.8) | 65.9(15.2) | 73.5(17.4) | |
irAE | 0.211 | |||
No | 90(73.8) | 41(67.2) | 49(80.3) | |
CIP | 19(15.6) | 11(18.0) | 8(13.1) | |
Other irAE | 13(10.7) | 9(14.8) | 4(6.6) | |
Treatment line | 0.847 | |||
Adjuvant | 21(17.2) | 11(18.0) | 10(16.4) | |
First-line | 77(63.1) | 38(62.3) | 39(63.9) | |
Second-line | 16(13.1) | 7(11.5) | 9(14.8) | |
Subsequent-line | 8(6.6) | 5(8.2) | 3(4.9) |
CIP, checkpoint inhibitors related pneumonitis; COPD, chronic obstructive pulmonary disease; DLco, diffusing capacity of the lung for carbon monoxide; ECOG, Eastern Cooperative Oncology Group; EGFR: epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; NA, not available; irAE, immune-related adverse events
*Values in the table represent means (standard deviation)